Singapore approves CMS’s ruxolitinib phosphate cream for nonsegmental vitiligo
November 6, 2026
Source: drugdu
51
China Medical System (00867.HK) announced on November 4 that Singapore’s Health Sciences Authority had approved Lumirix® (ruxolitinib phosphate cream) for nonsegmental vitiligo with facial involvement in adults and adolescents aged 12 and older. According to the company, it was Singapore’s first and, at the time, only topical prescription treatment that directly targets the underlying disease mechanism.
Source: http://finance.eastmoney.com/a/202611043922060662.html
Copyright©2026 Ddu. All rights reserved.
Read more on
- Boyi Group completes nearly 100 million RMB Series B financing November 6, 2026
- Net profit surges by 588%! A century-old traditional Chinese medicine brand successfully shifts gears. November 6, 2026
- China accepts United Laboratories’ semaglutide injection filing for weight management November 6, 2026
- Daridorexant receives US FDA Breakthrough Therapy designation for pediatric insomnia November 6, 2026
- Menovo subsidiary passes first US FDA on-site inspection for tildipirosin API November 6, 2026
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
